T 細胞治療市場規模、佔有率、成長分析、按方式、按類型、按適應症、按最終用戶、按地區 - 行業預測，2024-2031 年

2022年全球T細胞治療市場規模為28.3億美元，從2023年的38.3億美元成長到2031年的430億美元，在預測期間（2024-2031年）預計複合年成長率為35.3%。

癌症仍然是全球主要死亡原因之一，預計到 2040 年，癌症患者將增加 2,750 萬人。儘管現有的治療方法可以減緩疾病進展，但維持長期緩解仍然是一項挑戰。相較之下，免疫療法，尤其是 CAR-T、TCR 和 TIL 療法等 T 細胞療法，由於其副作用較少且能夠有效靶向和消除癌細胞而受到關注。這種創新方法利用了人體免疫系統的力量，並將 T 細胞療法定位為癌症治療的創新解決方案。隨著此類細胞療法的發展不斷加速，這一新興領域有望成為生物製藥產業最賺錢的市場之一。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 專利分析
• 案例研究

按治療類型和複合年成長率分類的 T 細胞治療市場規模（2024-2031）

• 市場概況
• CAR-T細胞療法
• 腫瘤浸潤淋巴細胞（TIL）療法
• 基於 T 細胞受體 (TCR) 的治療

T 細胞治療市場規模：按方式及複合年成長率 (2024-2031)

• 市場概況
• 研究用途
• 臨床使用

T 細胞治療市場規模：依適應症及複合年成長率（2024-2031）

• 市場概況
• 造血系統惡性
  • 淋巴瘤
  • 白血病
  • 多發性骨髓瘤
• 固態腫瘤
  • 惡性黑色素瘤
  • 肺癌
  • 大腸直腸癌
  • 乳癌
• 感染疾病
  • COVID-19
  • HIV
• 自體免疫疾病
  • 類風濕性關節炎
  • 多發性硬化症

T 細胞治療市場規模：依最終用戶及複合年成長率（2024-2031）

• 市場概況
• 醫院
• 癌症治療中心
• 調查機構

T 細胞治療市場規模：按地區及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• Kite Pharma（USA）
• Juno Therapeutics（USA）
• Adaptimmune（UK）
• Bluebird Bio（USA）
• Cellectis（France）
• Bellicum Pharmaceuticals（USA）
• Sangamo Therapeutics（USA）
• Atara Biotherapeutics（USA）
• Autolus Therapeutics（UK）
• Immatics（Germany）
• Allogene Therapeutics（USA）
• Mustang Bio（USA）
• Celyad Oncology（Belgium）
• Genocea Biosciences（USA）
• Iovance Biotherapeutics（USA）

結論和建議

Global T-Cell Therapy Market size was valued at USD 2.83 billion in 2022 and is poised to grow from USD 3.83 billion in 2023 to USD 43.0 billion by 2031, growing at a CAGR of 35.3% during the forecast period (2024-2031).

Cancer remains one of the leading causes of mortality worldwide, with projections indicating an addition of 27.5 million cases by 2040, imposing heavy financial, emotional, and physical strains on individuals and healthcare systems alike. While existing treatment options can slow disease progression, achieving long-lasting remission remains a challenge. In response, immunotherapies, particularly T-cell therapies such as CAR-T, TCR, and TIL therapies, are gaining traction for their ability to effectively target and eliminate tumor cells with fewer side effects. This innovative approach harnesses the human immune system's power, positioning T-cell therapy as a transformative solution in cancer treatment. As the development of these cell therapies continues to accelerate, this emerging sector is poised to become one of the most lucrative markets in the biopharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global T-Cell Therapy Market Segmental Analysis

Global T-Cell Therapy Market is segmented by therapy type, modality, indication, end-user and region. Based on therapy type, the market is segmented into CAR T-cell therapy, tumor-infiltrating lymphocytes (TIL) therapy and t cell receptor (TCR)-based therapy. Based on modality, the market is segmented into research use and clinical use. Based on indication, the market is segmented into hematologic malignancies, solid tumors, infectious diseases and autoimmune diseases. Based on end-user, the market is segmented into hospitals, cancer treatment centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is being significantly driven by the recent FDA approvals of Yescarta, Kymriah, and Tecartus, prompting numerous companies to pivot from developing traditional protein and small-molecule therapeutics to focus on adoptive therapies as their core business strategy. This shift has led to a remarkable increase in the T-cell therapy market, bolstered by strategic investments from both public and private sectors. The burgeoning gene therapy landscape plays a crucial role, as these advancements enhance the efficacy of CAR-T therapies. Additionally, the integration of T-cell approaches in cancer immunotherapy, combined with substantial funding dedicated to CAR T-cell research, is expected to propel the market, particularly with an expanding clinical trial environment for various hematologic cancers.

Restraints in the Global T-Cell Therapy Market

The T-cell therapy market faces significant constraints primarily due to the limited effectiveness of CAR-T therapies in treating solid tumors, compounded by safety concerns arising from the highly immunosuppressive tumor microenvironment. These challenges hinder market expansion, prompting industry stakeholders to explore innovative strategies to overcome these obstacles. Efforts are being made to enhance the applicability of CAR-T treatments in solid tumors, which may subsequently widen their therapeutic impact and improve patient outcomes. As the sector evolves, addressing these limitations will be crucial for tapping into the full potential of T-cell therapies in various oncological applications.

Market Trends of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is witnessing a notable trend towards the application of CAR T-cell therapies in the treatment of solid tumors, particularly in challenging cases such as diffuse midline glioma, a rare and aggressive pediatric cancer. Research highlights the potential of CAR T-cell treatment to significantly improve patient outcomes, with successful trials showing extended tumor eradication in animal models despite facing toxicity challenges. Intracerebroventricular (ICV) delivery methods are emerging as a safer, more efficient alternative to systemic administration, marking a pivotal shift in therapeutic strategies. This evolving landscape is expected to drive substantial growth in the T-Cell Therapy market, attracting investments and innovations tailored for solid tumor applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global T-Cell Therapy Market Size by Therapy Type & CAGR (2024-2031)

• Market Overview
• CAR T-Cell Therapy
• Tumor-Infiltrating Lymphocytes (TIL) Therapy
• T Cell Receptor (TCR)-Based Therapy

Global T-Cell Therapy Market Size by Modality & CAGR (2024-2031)

• Market Overview
• Research Use
• Clinical Use

Global T-Cell Therapy Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Multiple Myeloma
• Solid Tumors
  • Melanoma
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
• Infectious Diseases
  • COVID-19
  • HIV
• Autoimmune Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis

Global T-Cell Therapy Market Size by End-User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Research Institutes

Global T-Cell Therapy Market Size & CAGR (2024-2031)

• North America (Therapy Type, Modality, Indication, End-User)
  • USA
  • Canada
• Europe (Therapy Type, Modality, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellicum Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genocea Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations